Additionally, by demonstrating that loss-of-function variants in NFKBIE activates NFkB signaling in tumor cells, and by identifying differentially expressed genes involved in TNFalpha/NFkB signaling in our cohort, we are able to show that this may be an important biological pathway in melanoma patients undergoing anti-PD1 therapy. This evidence concerns the gene NFKB1 and neoplasm.